International Research Journal of Advanced Engineering and Science
ISSN (Online): 2455-9024

Advances in Understanding the Human Immune System: A Comprehensive Review of Recent Discoveries in Immunology and Their Implications for Treating Autoimmune Diseases and Infections

Loritta Anwuri Aka
Corresponding Author Email: akalorittaanwuri@gmail.com

Abstract— *Recent breakthroughs in immunology have brought forward new forms of immunotherapies for autoimmune diseases, infections, and cancer. This paper describes some new immune tolerance therapies, including CAR-T and Treg cell therapies, that schedule the immune system to replay instead of suppressing the pathogen-targeting immune response. Effects of pathogens such as HIV and SARS-CoV-2 on immune response, and the strategies used by pathogens to cover up are learned showing how immune modulation is used in treatment. The use of biomarkers and precision medicine in defining the prospects of personalization in medicine are discussed, providing real-time analysis of immune responses for HIV and rheumatoid arthritis. CRISPR technology is of key importance in improving genetic treatments of immunological disorders. However, it is still not possible to analyze all the niches of immune networks as well as ethical issues concerning immunotherapy and gene editing, as well as certain drawbacks of animal models. Further progress of the potential strategies aims to improve individualized therapy, identify biomarkers, and provide broader access to modern immunotherapies that may help create better healthcare interventions.*

Keywords—*Host-pathogen interactions, CRISPR technology, Immune evasion, Auto-immune diseases, Immunotherapy, Viral infections, Personalized medicine.*

I. Introduction

The human immune system is a multi-organ system that comprises cells, tissues, and organs that are responsible for detecting, neutralizing, and eliminating pathogens such as bacteria, viruses, fungi and parasites. It is broadly divided into two categories: The two types of immunity include innate immunity, which is fast and broad in its coverage, and adaptive immunity which is mediated by antigens of some specificity and longer duration. Innate immunity is the first line of defense that work via mechanisms like phagocytosis and cytokine release. The first type of adaptive immunity with T cells and B cells creates immunological memory, which is important for lasting protection [41]. They provide a mechanism for sustaining homeostasis by linking innate and adaptive immune systems to counter threats efficiently.

In the past decade, immunologists have come across significant achievements in understanding the mechanisms of the immune system. These findings have not only advanced the knowledge of the immune system but also provided radical treatments for various diseases. For instance, developments in understanding Immune checkpoint pathways, Regulatory T cells, and Immune tolerance have revolutionized the treatment of autoimmune diseases like Rheumatoid arthritis and Multiple sclerosis among others [51]. Furthermore, the development of immunotherapies such as monoclonal antibodies and mRNA vaccines have greatly changed the management especially of chronic infections not forgetting emerging pathogens such as SARS-CoV-2.

These advances underscore the importance of immunology in the practice of modern medicine they impact on everything from vaccines to cancer therapies. To this end, the present review aims at offering an up-to-date outlook on immunological advances with reference to autoimmune disorders and infections. This review will also show how advances in immunology are enabling more targeted therapeutic approaches based on an analysis of the literature collected over the past five years. Also, the paper will discuss current issues and future prospects in immunological studies and researches.

II. Methods

Peer-reviewed publications on biomarkers from the last ten years were compiled using searches on academic research publication data-bases such as PubMed, Science Direct, and Google Scholar. Publications, government, and regulatory agency reports, and directives were obtained through formal and informal means. The following keywords were used to search the literature: host-pathogen interactions, CRISPR technology, immune evasion, auto-immune diseases, immunotherapy, Viral infections, Personalized medicine, biomarkers and future directions.

III. Advances In Understanding The Human Immune System

A. Innate Immunity

The innate immune system is the first defense for the body providing a quick extraneous response to pathogens. Recent studies have provided further insights into the important function of innate immune cells, such as macrophages, neutrophils, and dendritic cells in immune regulation and sensing microbial pathogens.

1. Novel Findings Concerning the Effector Cells of the Initial Line of Defense

Loritta Anwuri Aka, "Advances in Understanding the Human Immune System: A Comprehensive Review of Recent Discoveries in Immunology and Their Implications for Treating Autoimmune Diseases and Infections," *International Research Journal of Advanced Engineering and Science*, Volume 9, Issue 4, pp. 258-266, 2024.

Phagocytes, granulocytes, and antigen-presenting cells are the major components of the innate immune system. Macrophages are highly specialized cells that identify, capture, and kill pathogens and also regulate inflammation in response to cytokines [20]. Neutrophils are short-lived cells possessing phagocytic capabilities that act expeditiously depending on the severity of the infection, particularly bacterial, by producing reactive oxygen species (ROS) and forming neutrophil extracellular traps (NETs) to encapsulate microbes [45]. Compared to other cells, dendritic cells have a special position because they are the link between innate and adaptive immunity. They also capture antigens and display them to T cells, thus participating in adaptive immunity [23]. Youth stress-associated changes have also been caught to reveal the flexibility of these innate immune cells to other microenvironments hence improving the immune response.

2. Role Of Pattern Recognition Receptors (PRRS) And Pathogen-Associated Molecular Patterns (PAMPS)

One of the central processes of innate immunity is pathogen recognition through pattern recognition receptors (PRRs). These receptors recognize conserved microbial structures referred to as pathogen-associated molecular patterns (PAMPs) found in viruses, bacteria, fungi, and parasites [58]. The most described category of PRRs is toll-like receptors abbreviated as TLRs. They are cell-surface receptors that detect diverse PAMPs including bacterial lipopolysaccharides (LPS) and viral RNA through interactions with specific receptors on immune cells leading to intracellular signaling pathways culminating in the production of inflammatory cytokines and type I interferons [4]. This process not only contributes to the destruction of the pathogen but also triggers the functioning of other components of the immune system, including adaptive immunity.

Not only TLRs but also some other PRRs, NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) are involved in the identification of intracellular pathogens and signaling in immune responses. For instance, NLRs are involved in the identification of bacterial products inside the cytoplasm and the activation of inflammasomes [58]. These findings have added another layer of functionality to PRRs and provided new information on how these receptors can adapt the immune response depending on the invader.

3. Advances in inflammasome research

Inflammasomes are protein complexes produced based on infections or cell stress, which play an essential role in the progression of inflammation. They support further differentiation and release of the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) which are required for the immune defense [3]. More attention has been paid to other inflammasomes, such as the NLRP3 inflammasome, in the development of diseases. Inflammasomes, on one hand, play a critical role in host defense against infections, and on the other hand, the overactivation of the inflammasome is associated with inflammation and auto-immune disorders including gout, type 2 diabetes, and atherosclerosis [22].

Recent studies on different inflammasomes have shown that many pathogens are capable of suppressing or avoiding inflammasome activation to survive in a host. For instance, certain viruses and bacteria have ways of obstructing the formation of the NLRP3 inflammasome, thereby weakening the strength of the immune response of the host [35]. These findings therefore hold the promise of targeting inflammasomes both as an effective treatment for infectious diseases as well as an anti-inflammatory therapy. Pharmacological interventions targeting inflammasome have not been developed yet but are in the developmental pipeline, and the goal is to treat issues from infections to chronic inflammatory diseases.

B. Adaptive Immunity

The adaptive immune system targets pathogens and foreign antigens with great selectivity and involves the T cells and B cells. Recent developments in the study of adaptive immunity have greatly improved our understanding of T cell and B cell responses, functions of memory cells in long-term immunity, and the multistep model of antigen presentation at the immunological synapse.

1. New Insights in T and B Cell Response

T cells and B cells are concerned with adaptive immunity. Recent findings have refined the knowledge of the differentiation process of these cells and how they relate to pathogens. T cells, particularly CD4+ T helper (Th) cells, have been identified to ‘‘reprogram,’’ or differentiate, into various functional subsets, which include Th1, Th2, Th17, and Tregs with unique contributions to immunity and tolerance [69]. This specialization allows a specialized response depending on the pathogen, ranging from viruses within cells to extracellular bacteria, and parasites. Also, recent studies have shown that cytotoxicity CD8 + T cells can kill virus-infected or tumor cells by secretion of perforin and granzymes [25].

B cells, on the other hand, differentiate into antibody-secreting cells whose task is to neutralize pathogens and enhance their elimination. One of the major recent developments is the identification of somatic hypermutation and class-switch recombination for the production of high-affinity antibodies [40]. These processes provide that B cells are in a position to produce antibodies that can counteract infections of a very broad range and knowledge of these mechanisms is a key factor in the creation of better vaccines.

2. Role of Memory T Cells and B cells in Long Term Immunity

Memory T cells and B cells are significant for long- term immunity. Upon exposure to a pathogen, some of the cells in the immune system differentiate into memory cells that “recall” the pathogen and respond quicker and much stronger the next time. One of the latest works in scientific practice unveils the subtypes of memory T cells, such as central memory T cells and effector memory T cells, which localize in tissues to maintain protection [50]. For instance, tissue resident memory T cells (TRM) dwell in skin and lungs and afford rapid response at the portal of viral re-exposure [47]. These observations indicate that memory T cells are not only crucial for systemic immunity but also for site-specific protection.

Loritta Anwuri Aka, “Advances in Understanding the Human Immune System: A Comprehensive Review of Recent Discoveries in Immunology and Their Implications for Treating Autoimmune Diseases and Infections,” *International Research Journal of Advanced Engineering and Science*, Volume 9, Issue 4, pp. 258-266, 2024.

Memory B cells also contribute to sustained immunity because they create antibodies many days after infection or immunization. These cells when reminded of its specific antigen can quickly differentiate into plasma cells that make it effective in humoral response. Recent studies have revealed that the durability of memory B cells as well as long-lived plasma cells, particularly residing in the bone marrow, for continuous antibody making and immunity [31]. This is important in terms of vaccine development given that T-cells can form long-lasting immunity against diseases such as influenza, COVID-19, and more.

3. *New Knowledge About Immunological Synapses and Antigen Presentation*

T cells can work in concert with antigen-presenting cells (APCs) for effective activation of adaptive immune mechanisms. This interaction takes place at the immunological synapse, a site specific interaction involving the T cell receptors (TCRs) limited to the T cell identifying to antigenic peptides by the major histocompatibility complex (MHC) molecules on the surface of APCs [13]. Technological innovation, especially in imaging techniques like high-resolution microscopy has made it possible to observe dynamics of the immunological synapses and the precise molecular ballet, which results in effective antigen presentation and T cell activation [5].

Moreover, new evidence has shown that co-stimulatory receptor CD28 and inhibitory receptor CTLA-4 regulate T cell activation in the immunological synapse. CD28 was found to deliver co-stimulatory signals that promote T cell activation, whereas CTLA-4 is an inhibitory receptor that helps to restrain T cell reactivity to avoid excessive activation and autoimmunity [65]. Moreover, the activation and inhibition of effector functions are crucial at the immunological synapse to avoid pathogenic effects on the host organism.

There have also been numerous improvements in the process of antigen presentation as seen in the way dendritic cells present antigens through both MHC class I and II expression. In cross-presentation, dendritic cells present extracellular antigens on MHC class I to CD8+ T cells, which has been demonstrated to be imperative for antiviral and antitumor immunity [63]. Such findings are contributing to the formation of a new generation of cancer immunotherapy and vaccination where one strategy to boost immunity is through increasing antigen presentation.

C. Immune Regulation and Tolerance

The immune system needs tight control to avoid overactivation or dysregulation that could result in autoimmunity or chronic inflammation. Immunoregulation and immunotolerance are essential for the establishment of self-tolerance and to make sure that the immune system can differentiate between pathogens and self-antigens. Other preemptive processes of immune regulation include actions of regulatory T cell, immune checkpoint signaling, cytokine, and chemokine signaling.

1. *Regulatory T Cells (Tregs) and Their Function in Immune Tolerance.*

Tregs are essential components of the immune system that are primarily responsible for the immune tolerance and immunity to autoimmunity. These cells, which express transcription factor Foxp3+ for example are responsible for correcting overactive immune responses and preventing the body's immune system from attacking its own tissues. Tregs inhibit effector T cells through the production of anti-inflammatory cytokines, including interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) and through cell contact [43]. New data in the last few years enriched the concept of Treg plasticity, which means that these cells can undergo transcriptional reprogramming, depending on the surrounding microenvironment and affecting suppression activity. For instance, Tregs can perform specialized functions in the skin or the gastrointestinal tract to regulate immune responses locally [68]. Knowledge about the processes that govern the functioning and regulation of Tregs is important for designing novel treatments for autoimmune disorders and enhancing the success of organ transplantation.

2. *Recent Developments on the Understanding Of Immune Checkpoint Pathways (CTLA-4, Pd-1)*

There are immune checkpoint pathways that are crucial to control immune activation and provide tolerance such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). PD-1 and CTLA-4 are implicated as immune checkpoints that restrain T cell activation and activity [65]. CTLA-4 binds to B7 molecule on the surface of APCs and have an antagonistic effect with CD28, which enhances the activation of T cells [7]. PD-1, unlike TIM-3, interacts with its ligands, PD-L1 and PD-L2 on APCs and different organs/tissues and provides co-inhibitory signals that suppress T cell function predominantly in peripheral tissues.

Subsequent findings have shown that cancer cells use these checkpoint pathways to avoid being targeted by the immune system. Through upregulating PD-L1, tumors are able to suppress T cell responsiveness and evade immune surveillance. This has led to the emergence of ICI treatments like anti-CTLA-4 and anti-PD-1/PD-L1 which removes the inhibitory signals and enables T cell to act against the cancer [65]. Even though, these therapies have hugely impacted cancer treatment, the current research concentrates on the larger aspect of immune checkpoint regulation in autoimmune disease, chronic infection, and tissue transplant tolerance.

3. *Regulation of Cytokines and Chemokines in Immune Modulation*

Cytokines and chemokines are extracellular proteins that act as signalers in cells with immunological functions. They interact directly with immune cells and are critical for regulation of both inflammatory and anti-inflammatory signaling. Hence, pro inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), Interleukin-6 (IL-6), Interferon-gamma (IFN-γ) boost up immune response and inflammation while anti-inflammatory cytokines like Interleukin-10 (IL-10) and TGF-β dampen the immune response and fosters tolerance [43].

Chemokines, in contrast, play a central role in the regulation of immune cell trafficking towards areas of

Loritta Anwuri Aka, "Advances in Understanding the Human Immune System: A Comprehensive Review of Recent Discoveries in Immunology and Their Implications for Treating Autoimmune Diseases and Infections," *International Research Journal of Advanced Engineering and Science*, Volume 9, Issue 4, pp. 258-266, 2024.

inflammation or tissue damage. They attach to receptors on immune cells known as chemokine receptors, which direct the migration of leukocytes such as T cells, B cells and macrophages to sites of interest [21]. In this regard, the regulation of pro-inflammatory and anti-inflammatory cytokines and chemokine signals is essential for better understanding of immune homeostasis. Abnormal regulation of cytokine and chemokine signaling may result in chronic inflammation, autoimmunity, or immunodeficiency [43]. Recent breakthroughs in the study of cytokines and their role in the immune system have given new insights into this area with cytokine antagonists being targeted therapeutically for the treatment of autoimmune diseases and inflammatory conditions.

IV. New Findings In Autoimmune Diseases

Autoimmune disorders are illnesses in which the immune system destroys healthy cells and tissues. This self-destructive activity results from genetic endowment as well as environmental stimuli and overwhelming immunological phenomena.

A. Origin of Autoimmunity Outline: The Genetics and the Environment

The research in the recent past has therefore focused on the understanding of the genetic and environmental factors that influence the development of autoimmune diseases. Genetic predisposal has been thought to be closely related to certain gene variants and among them are genes that influence immune system, including HLA genes. Polymorphisms in these genes can affect the ability of immune cells to recognize self-antigens and render people susceptible to autoimmune responses [32]. An individual is also likely to develop autoimmune diseases if they get infected, exposed to toxins, or through their diet. For example, viral diseases like Epstein-Barr virus have shown to be associated with diseases like multiple sclerosis and lupus, as they may trigger an autoimmune reaction in susceptible genetic profiles [24]. Furthermore, smoking and UV exposure are two other epidemiological environment associated with diseases such as rheumatoid arthritis and lupus [67].

1. Role of Molecular Mimicry and Bystander Activation

Molecular mimicry involves the cross-reactivity of foreign antigens with self-antigens and causes the immune system to attack both the pathogen and host tissues. This mechanism has been associated with diseases like Guillain-Barré syndrome and type 1 diabetes [34]. For instance, in Guillain-Barré syndrome, the immune system targets the nerves following an infection with Campylobacter jejuni because it regards the myelin sheath proteins as bacterial antigens. Bystander activation, in contrast, occurs when an infection or inflammation recruits immune cells non-specifically and triggers an autoimmune process.

This process is often seen in chronic viral diseases where the body is at a state of constant high alert for pathogens, which may inadvertently result in autoimmunity [64]. Consequently, molecular mimicry and bystander activation are two major routes through which infections can cause autoimmune diseases in susceptible hosts.

2. New Insights into Epigenetic Regulation of Autoimmunity

The role of DNA methylation, histone modifications, and non-coding RNAs has become pivotal for the investigation of immune regulation in autoimmune diseases. These modifications do not affect DNA sequence, but can change the function of the genes, in turn, affecting the behavior of the immune cells. Dysregulated epigenetic profiles have been reported in many autoimmune disorders, such as SLE and RA. For example, reduced DNA methylation has been found in immune cells in SLE patients wherein it results in increased expression of genes involved in immune response to self-antigen [61].

With the development of techniques like high-throughput sequencing, scientists have been able to pinpoint where these epigenetic changes occur. Such studies have gone further in showing that external factors such as infections, stress, and diet can modify epigenetic markers, demonstrating the intricate interplay between genes and the environment in autoimmune diseases [1]. These realisations reveal entirely novel approaches in the treatment of autoimmune diseases using therapeutic methods that reverse epigenetic mechanisms.

B. Therapeutic Advances In Autoimmune Diseases

Currently, auto-immune diseases are characterized by a rapidly changing therapeutic mosaic, where the emphasis is on more sophisticated and individualized treatment. Some of these developments include the biologic therapies, the small molecule inhibitors, and the tolerogenic or immunotherapy based strategies.

1. Biologic Therapies

Biologic Therapies include Tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, and other medications that are used for the treatment of psoriasis. Targeted biologic therapies are effective in the management of autoimmune diseases by directly affecting components of the immune system. TNF inhibitors like infliximab and adalimumab are among the earliest biologics and they have received good evidence for their efficacy in diseases including RA, Crohn's disease and psoriasis [57].

These agents operate by antagonizing TNF, an inflammatory cytokine that plays a role in the development of many autoimmune diseases. However, TNF inhibitors not only decrease inflammation indicators but also decelerate the therapeutic course of many patients [17].

However, more recently, there has been an increase in the use of monoclonal interleukin (IL) 17 inhibitors like secukinumab in treatment of psoriasis and ankylosing spondylitis. Specifically, IL-17 is implicated in driving inflammation in these diseases, and the use of IL-17 inhibitors has been shown to lead to substantial symptomatic and quality-of-life benefits for patients [26]. Another crucial biologic class works by inhibiting IL-6 and its receptor, out of which the most widely used is tocilizumab; especially for rheumatoid arthritis (RA) patients for whom TNF inhibitors are ineffective [19].

Loritta Anwuri Aka, "Advances in Understanding the Human Immune System: A Comprehensive Review of Recent Discoveries in Immunology and Their Implications for Treating Autoimmune Diseases and Infections," *International Research Journal of Advanced Engineering and Science*, Volume 9, Issue 4, pp. 258-266, 2024.

2. *Recent Developments In Small Molecule Inhibitors (JAK Inhibitors, BTK Inhibitors)*

Small molecule inhibitors constitute yet another mainstream pharmacological intervention category for autoimmune diseases that has the potential to be used in place of biologics since they can be administered orally. Tofacitinib and baricitinib, which are JAK inhibitors, are authorized for the management of RA and ulcerative colitis patients. Janus Kinase (JAK) inhibitors work by inhibiting the actions of JAK enzymes which are part of the signaling pathways of various inflammatory cytokines including IL-6 and interferons [42]. JAK inhibitors have been proven to be effective in managing disease activity and improving patients' outcomes including those who failed to respond to biologic agents [60].

Bruton's tyrosine kinase (BTK) inhibitors, a more recent class of small molecules, are also in development for autoimmune diseases with systemic lupus erythematosus (SLE) and multiple sclerosis (MS) being the most prominently featured. BTK is involved in B-cell receptor signaling and blocking this pathway can decrease activation of B-cells, which is a critical component in many autoimmune diseases [38]. BTK inhibitors like evobrutinib are still in the early stages of clinical trials but have demonstrated success in lowering the activity of SLE and MS.

3. *Tolerogenic Therapies And Immunotherapeutic Strategies*

Another promising approach to the treatment of autoimmune diseases is the development of therapeutic strategies that are based on the conception of immune tolerance. The aim of these strategies is to restore immunological tolerance to self-antigens while retaining efficient immunity to pathogens. Tolerogenic treatments involves tolerogenic dendritic cells, Treg cell therapy, and antigen-specific immunotherapy.

Recent developments in the function of Tregs aim to strengthen the T cell and the added gene to function to reduce autoimmunity. Animal models and early phase clinical trials have shown the effectiveness of Tregs in treating type 1 diabetes and MS, as resistance of immune tolerance would prevent the disease's progression [16].

Another promising approach that can be categorized under immunomodulation is antigen-specific immunotherapy, including peptide-based vaccines, which initiates an immune response capable of selectively restituting immune tolerance to certain autoantigens without suppressing the overall immune response. More studies are needed in this area, but some studies in patient-specific genetic diseases, such as type-1 diabetes, indicate that targeted therapies may help prevent the immune system from attacking pancreatic beta cells [56].

Other immunotherapy strategies like chimeric antigen receptor (CAR) T-cell therapy that has shifted the landscape of cancer treatment is also being seeking in autoimmune diseases. Initial observations indicate that CAR-T cells can be significantly designed to home in on pathologic immune cells in autoimmune diseases, making this treatment personalized and highly specific because normal tissues are not affected [15].

C. Immunology Of Infections

These host-pathogen interactions form the basis for the understanding of immunity and response to infections. These interactions consist of an often intricate warfare between the host immunity system and the ways in which the pathogen can avoid the host's immune system. It has become clear how pathogens hide from our immune defenses and how our immune system in turn combats viral, bacterial or fungal threats.

1. *New Developments In Host-Pathogen Interactions*

Viruses and other parasites are able to form complex strategies of escaping the host immune response and, therefore, thrive within the host organism. For instance, viruses exploit the host cell and learn how to control immune responses in order not to be detected. Herpes viruses, in particular, are notorious for disrupting the immune response because they can suppress the expression of viral antigens on the cell surface to prevent the recognition of T cells through major histocompatibility complex (MHC) molecules [14]. Likewise, some bacteria like Mycobacterium tuberculosis are capable of prolonged survival within host macrophages and do not undergo phagosome maturation as a way of avoiding immune clearance from the host [6].

For instance, fungal pathogens like Candida albicans employs numerous mechanisms to avoid detection by PRR of the host such as the ability to modify the composition of cell wall to escape identification [66]. Further, it aids immune tolerance through regulation of such pro-inflammatory profiles hence sustaining chronic infection in immune compromised hosts.

2. *Progress In Knowledge Of The Immune Response To Viruses (HIV, SARS-COV-2)*

In the field of viral immunology, considerable progresses have been made in fighting chronic viral diseases such as HIV infection and novel emergent virus like SARS-CoV-2. To this end, HIV has been a paradigmatic virus for analyzing viral latency and immune escape mechanisms. Regarding the immune evasion strategies, one of the most notable is the high replication rate of the HIV virus which, thereby, causes high mutation, and antigenic variation to allow the virus to escape neutralizing antibodies [52]. Also, HIV has the ability to infect cells that have a long half-life; these include cells where the virus lies dormant and is not easily targeted by the immune system or antiretroviral therapy (ART) [10].

The COVID-19 pandemic caused by the SARS-CoV-2 virus has stimulated significant efforts in understanding how the immune system responds to coronaviruses. COVID-19 is caused by SARS-CoV-2 which uses the spike protein to gain access to host cells through the receptor called angiotensin converting enzyme 2 (ACE2) and also suppresses the innate immune response through inhibition of interferons [2]. This immune evasion leads to the hyper inflammatory response that is espoused in severe COVID-19, where the cytokine storm results in tissue damage and multiorgan dysfunction as described by [59]. The immunity generated by adoptive immunity proved useful in creating strong immunity to the SARS-CoV-2 virus through vaccines and therapies such as mRNA vaccines [48].

3. Current Knowledge On The Immune Reaction To Bacterial And Fungal Infections

Bacterial infections trigger an immune response that varies based on the type of bacteria and its location in the body. The immune system employs neutrophils and other phagocytic cells for clearance of the extracellular bacteria such as the staphylococcus aureus. Nonetheless, some bacteria can avoid the recognition by immune receptors through various strategies like creating a biofilm or secreting molecules that suppress the immune response [18].

However, extracellular pathogens like Listeria monocytogenes that infects inside the cells are distinct requiring the use of CD8+ T cells which are important in the recognition and elimination of the infected cells [70]. Further, knowledge on bacterial toxins has helped us understand how bacteria can trick the immune system into becoming overly active or, conversely, non-functional.

This paper aims to reveal the intricate mechanism of immune response to fungi and their products, and because of the ambidextrous roles of innate and adaptive immunity. Candida albicans infections are managed by Th17 cells, which secrete IL-17 and attract neutrophils to the site of infection [33]. However, in immune-compromised patients, the patients with AIDS or the patients with cancer who are under chemotherapy, their immune system is not functioning well to mount effective immune response to fungi resulting to chronic or systemic mycoses.

V. Implications For Future Therapeutics And Personalized Medicine

Immunology research has provided the basis for improved targeted therapeutic approaches to managing infections and immune system diseases. However, with a general advance in understanding the immune response and the possibility of determining individual levels of immune response, the use of biomarkers, and genetic therapies, the concept of personalized medicine is becoming a possibility.

1. Precision Medicine in Immunology: Tailoring Treatments to Individual Immune Profiles

Precision Medicine ITs goals include developing treatments for different diseases based on individual characteristics of the patient and their immune response. This strategy takes into consideration the fact that immune system reactions to pathogens are unique to each individual, depending on the genetic predispositions, previous experiences, and the state of health of a patient. For this reason, treatments that prove helpful in managing the condition in one patient may not have the same impact on another patient.

In infectious diseases and autoimmune conditions, one can define the immune response for a given individual and then develop a treatment regimen that will inhibit or modify the immune response. For example, in the case of viral infections such as HIV, patient Human leukocyte antigen (HLA) type and immunological reaction can be used to predict the response of ART and the possibility of developing anti-drug resistance [55]. Also, in diseases, like rheumatoid arthritis, biologic agents that target a cytokine of a choice (for instance, TNF or IL-6) can be chosen in accordance with an immune profile of a patient, so the therapy outcomes would be better as would be the side effects [57].

2. Application of Biomarkers in Measuring Disease Progression and Predicting to Treatment Outcome

Biomarkers are used more frequently in personalized medicine since they help track disease progression and the response of the patient to therapy. These molecular markers can be cytokines, genetic abnormalities, certain types of immune cells, and, thanks to them, clinicians can track the state of the immune system in real-time.

In managing HIV, biomarkers include the viral load which measures the quantity of the virus in the patient's blood and the CD4+ T cell count which measures the quantity of specific immune cells in the patient's blood [10]. In the context of COVID-19, some specific biomarkers including elevated IL-6 and C-reactive protein (CRP) have been reported to be linked up with poor prognosis and therefore monitoring these biomarkers can inform therapeutic management [11].

Likewise, the level of autoantibodies in autoimmune diseases can indicate disease activity or progression. For instance, anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis or anti-double-stranded DNA antibodies in lupus are useful diagnostic markers that help in stage-specific management interventions [62].

3. Recent Developments in Gene Therapy and CRISPR Technology in Managing Immunological Disorders

Gene therapy and CRISPR technology can be considered as new paradigms in developing approaches for the immune-modulatory therapy and correction of immune deficiency diseases on the genetic level. Gene therapy has been successfully applied in the treatment of inherited immune deficiencies like Severe Combined Immunodeficiency (SCID), where the genes in immune cells are replaced with viral vectors [28].

CRISPR-Cas9 technology takes this a step further by enabling the modification of the genome directly. This tool can be used to treat various immune disorders such as frequent and persistent infections, autoimmune disorders. For instance, CRISPR has been deployed in a trial to genetically reprogram immune cells in a bid to enhance the efficacy of managing chronic viral infections such as HIV [27]. Compared to the existing antiviral medications which just control the viremia, CRISPR holds the promise of achieving sustained viral eradication or even a cure.

In addition, utilizing CRISPR for autoimmune disorders entails changing specific genes that make people prone to diseases such as type 1 diabetes or multiple sclerosis. On the other hand, CRISPR can be used to edit immune cells like a regulatory T cell to enhance its capability to reducing autoimmune response [36]. These approaches represent a high potential for the development of individualized treatment that would require completely different immune response and genetic information.

VI. Challenges And Future Directions

1. *Current Limitations of Immunological Research*

There have been tremendous achievements made in immunological research over the last centuries, but there are still certain challenges that continue to slow the rate of future developments as well as contemporary therapies. The complexity of the immune system itself is one of the major challenges. The immune response is a complex cellular network consisting of numerous cells that utilize signaling pathways which are still unknown to some extent. These factors can be influenced by genetics, epigenetics, and environmental conditions, which makes it challenging to anticipate the immune system's response to infections, autoimmune disorders, or other therapies, resulting in variability among people [8].

Therefore, the limitation of using animal models to study immune responses may also be considered as a weakness. Although animal models are crucial for conducting preclinical research, inherent dissimilarities in immune responses between species mean that drugs may not be effective or can cause side effects when tested in humans [37]. Moreover, immune related diseases and diseases caused by chronic infections have different picture in patients so the treatment has to be individual.

Furthermore, in spite of some recent advances in the discovery of immune biomarkers, there is currently no accurate biomarker to measure the progression of many diseases or the effectiveness of treatments for them. This is especially true in conditions like cancer or autoimmune system diseases where early detection could determine a patient's status [9].

2. *Contemporary Innovation Ideas (Single-Cell Sequencing, CRISPR) and Their Potential Impact on Future Discoveries*

Single cell sequencing and CRISPR technologies can be seen as the most promising ones in mitigating some of the mentioned limitations in immunological research. RNA sequencing technology lets scientists characterize a single cell's transcriptome with ease, which provides valuable information about the variability of immune cell populations and how they can work in health and sickness. It has also been used to uncover the mechanism of inter-cell communication in interaction between immune cells in the tumor microenvironment for cancer immunotherapy [44]. Thus, in addition to discovering how different subsets of immune cells express the genes, investigators are able to detect low-probability cells and new immunological signaling routes that may not be observed in collective investigations.

CRISPR-Cas9 system is a powerful tool that has provided an efficient method for modulating the genetic makeup of an organism. In immunology, CRISPR has been used to establish new models of immune response genetics by knocking out or changing specific genes. For instance, CRISPR is being used to modify immune cells to enhance their ability to combat infections or even cancer or autoimmune disorders. One of the benefits of the CRISPR-based treatments is the chance to cure genetic diseases based on immune dysfunction and get rid of conditions like sickle cell anemia or HIV [12]. Furthermore, CRISPR screening approaches allow for the determination of immune cell genes involved to create new therapies [21].

3. *Ethical Issues Regarding Immune-Based Treatments*

With immune-based therapies and genetic technologies such as CRISPR/Cas 9 coming to the forefront, many ethical issues arise. The first fear is that the editing of the genome may cause unintended changes that could harm the individual or cause an immune response [29]. It is important to have a regulated and safe method of applying CRISPR before going to the clinical stage, especially if germlines are targeted.

Immunotherapies like CAR-T cell therapy also pose ethical concerns. Such therapies are costly; this creates concerns of affordability and equality. Low-income patients may not afford these advanced treatments, thus worsening the inequality in care provision [39]. In addition, questions about patient autonomy and the mitigation of risks stem from potential side effects of the treatment, including cytokine release syndrome in CAR-T cell therapy.

The second ethical implication stems from the possible misuse of immune-based technologies, which has not been described in this article, yet is an important consideration that can inform future studies. For instance, it is suggested that through CRISPR, people could theoretically be improved in terms of desirable characteristics, thus raising concerns regarding the so-called "designer babies" and the general future of eugenics in society [30]. Over time, certain measures and policies will have to be put in place to help address the major issues pertaining to the utilization of these technologies, while at the same time embracing the positive benefits that emerge from research.

VII. Conclusion

In recent years, advancements in immunology have led to significant breakthroughs in understanding the body's immune responses, opening new avenues for disease treatment. Key findings, such as the identification of novel biomarkers, therapeutic targets, and immune cell pathways, have fundamentally changed our understanding of autoimmune diseases and infections. These insights underscore the intricate relationship between the immune system and disease processes, enabling more targeted, personalized, and less invasive treatment approaches.

The future of immunology holds immense potential for further breakthroughs. With the integration of cutting-edge technologies such as CRISPR, next-generation sequencing, monoclonal antibodies, and personalized vaccines, we are poised to unlock new dimensions of immune regulation. These tools offer exciting opportunities to not only treat autoimmune disorders and infections more precisely but also address complex conditions like cancer and chronic inflammatory diseases. As these innovations evolve, they may pave the way for therapies that can manipulate immune responses with unprecedented precision, offering cures for diseases that have long been considered untreatable.

Loritta Anwuri Aka, "Advances in Understanding the Human Immune System: A Comprehensive Review of Recent Discoveries in Immunology and Their Implications for Treating Autoimmune Diseases and Infections," *International Research Journal of Advanced Engineering and Science*, Volume 9, Issue 4, pp. 258-266, 2024.

The transformative impact of these discoveries is already being felt in clinical settings. In the management of autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis, we now have therapies that modulate the immune system more effectively, reducing harmful side effects and improving patient outcomes. Meanwhile, treatments for infections are increasingly focused on enhancing the immune system's ability to combat pathogens, minimizing antimicrobial resistance, and speeding up recovery times. As we continue to build on these findings, the potential for immunology to revolutionize healthcare is undeniable. From reducing the burden of chronic diseases to potentially eradicating some of the most challenging conditions, the future of immunology is bright and full of promise.

ACKNOWLEDGMENT

The author wishes to express gratitude to all who contributed to the success of this work.

REFERENCES

[1] Alonso, S., & Cooper, G. S. (2021). Epigenetics in systemic lupus erythematosus. Journal of Autoimmunity, 123, 102698. https://doi.org/10.1016/j.jaut.2021.102698
[2] Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W. C., Uhl, S., Hoagland, D., Møller, R., & tenOever, B. R. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181(5), 1036-1045. https://doi.org/10.1016/j.cell.2020.04.026
[3] Broz, P., & Dixit, V. M. (2016). Inflammasomes: Mechanism of assembly, regulation and signalling. Nature Reviews Immunology, 16(7), 407-420. https://doi.org/10.1038/nri.2016.58
[4] Brubaker, S. W., Bonham, K. S., Zanoni, I., & Kagan, J. C. (2015). Innate immune pattern recognition: A cell biological perspective. Annual Review of Immunology, 33, 257-290. https://doi.org/10.1146/annurev-immunol-032414-112240
[5] Cai, E., Teo, T. H., Sun, Y., & Schmid, E. M. (2018). Dynamic imaging of T cell receptor signaling in the immunological synapse. Nature Immunology, 19(4), 362-373. https://doi.org/10.1038/s41590-018-0057-7
[6] Cambier, C. J., Falkow, S., & Ramakrishnan, L. (2014). Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell, 159(7), 1497-1509. https://doi.org/10.1016/j.cell.2014.11.024
[7] Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2020). CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annual Review of Immunology, 29, 72-89. https://doi.org/10.1146/annurev-immunol-032409-132608
[8] Chaplin, D. D. (2020). Overview of the immune response. Journal of Allergy and Clinical Immunology, 125(2), S3-S23. https://doi.org/10.1016/j.jaci.2009.12.980
[9] Cheng, S., Li, Z., Gao, R., Xing, B., Gao, Y., Yang, Y., & Zhang, Z. (2021). A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell, 184(3), 792-809. https://doi.org/10.1016/j.cell.2021.01.022
[10] Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2016). The end of AIDS: HIV infection as a chronic disease. The Lancet, 382(9903), 1525-1533. https://doi.org/10.1016/S0140-6736(13)61809-7
[11] Del Valle, D. M., Kim-Schulze, S., Huang, H. H., Beckmann, N. D., Nirenberg, S., Wang, B., & Merad, M. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 26(10), 1636-1643. https://doi.org/10.1038/s41591-020-1051-9
[12] Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096. https://doi.org/10.1126/science.1258096
[13] Dustin, M. L., & Long, E. O. (2019). Cytotoxic immunological synapses. Immunity, 31(1), 111-122. https://doi.org/10.1016/j.immuni.2019.06.020
[14] Eisenberg, R. J., Atanasiu, D., Cairns, T. M., Gallagher, J. R., Krummenacher, C., & Cohen, G. H. (2020). Herpes virus fusion and entry: A story with many characters. Viruses, 12(1), 98. https://doi.org/10.3390/v12010098
[15] Ellebrecht, C. T., Bhoj, V. G., Nace, A., Choi, E. J., Mao, X., Cho, M. J., & Payne, A. S. (2016). Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science, 353(6295), 179-184. https://doi.org/10.1126/science.aaf6756
[16] Ezzelarab, M. B., & Thomson, A. W. (2020). Tolerogenic dendritic cells and regulatory T cells: Endogenous and exogenous tolerogenic therapy for autoimmunity. Frontiers in Immunology, 11, 581227. https://doi.org/10.3389/fimmu.2020.581227
[17] Feldmann, M., Maini, R. N., & Bondeson, J. (2020). Anti-TNF therapy: Mechanisms of action using TNF transgenic mice to resolve the mystery of the effectiveness of TNF blockade in rheumatoid arthritis. Cytokine & Growth Factor Reviews, 55, 39-46. https://doi.org/10.1016/j.cytogfr.2020.06.001
[18] Foster, T. J. (2019). Immune evasion by Staphylococcus aureus. Nature Reviews Microbiology, 17(1), 25-40. https://doi.org/10.1038/s41579-018-0101-0
[19] Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., & Takiya, L. (2018). Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis: A Phase III randomized, controlled trial. The Lancet, 391(10135), 748-759. https://doi.org/10.1016/S0140-6736(17)32451-1
[20] Gordon, S., & Plüddemann, A. (2017). Macrophage clearance of apoptotic cells: A critical assessment. Frontiers in Immunology, 8, 1048. https://doi.org/10.3389/fimmu.2017.01048
[21] Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014). Chemokines and chemokine receptors: Positioning cells for host defense and immunity. Annual Review of Immunology, 32, 659-702. https://doi.org/10.1146/annurev-immunol-032713-120145
[22] Guo, H., Callaway, J. B., & Ting, J. P. (2015). Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nature Medicine, 21(7), 677-687. https://doi.org/10.1038/nm.3893
[23] Hammer, G. E., & Ma, A. (2019). Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annual Review of Immunology, 37, 595-619. https://doi.org/10.1146/annurev-immunol-042718-041507
[24] Harley, J. B., Chen, X., Pujato, M., Miller, D., Maddox, A., Forney, C., & Kaufman, K. M. (2018). Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nature Genetics, 50(5), 699-707. https://doi.org/10.1038/s41588-018-0102-3
[25] Harty, J. T., & Badovinac, V. P. (2018). Shaping and reshaping CD8+ T-cell memory. Nature Reviews Immunology, 18(1), 77-86. https://doi.org/10.1038/nri.2017.118
[26] Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D., & Colombel, J. F. (2019). Secukinumab, a human anti–IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomized, double-blind placebo-controlled trial. Gut, 68(5), 738-746. https://doi.org/10.1136/gutjnl-2018-316023
[27] Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., & Thiel, E. (2019). Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. New England Journal of Medicine, 360(7), 692-698. https://doi.org/10.1056/NEJMoa0802905
[28] Kohn, D. B., Booth, C., & Kang, E. M. (2021). Gene therapy for inherited immunodeficiencies: state of the art. Frontiers in Pediatrics, 9, 702-736. https://doi.org/10.3389/fped.2021.702736
[29] Lander, E. S., Baylis, F., Zhang, F., Charpentier, E., Berg, P., Bourgain, C., & Daley, G. Q. (2019). Adopt a moratorium on heritable genome editing. Nature, 567(7747), 165-168. https://doi.org/10.1038/d41586-019-00726-5
[30] Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015). Don't edit the human germ line. Nature, 519(7544), 410-411. https://doi.org/10.1038/519410a
[31] Lanz, H. L., Clapham, H. E., & Downham, M. (2022). Memory B cell responses following vaccination. Nature Immunology, 23(2), 171-183. https://doi.org/10.1038/s41590-021-01113-9
[32] Li, Y., Qiu, X., Zhang, Z., & Wu, Q. (2021). Genetic predisposition and autoimmune diseases. Autoimmunity Reviews, 20(3), 102756. https://doi.org/10.1016/j.autrev.2020.102756

[33] Lionakis, M. S., & Netea, M. G. (2013). Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathogens, 9(6), e1003079. https://doi.org/10.1371/journal.ppat.1003079
[34] Luo, J., Zhang, Y., & Ding, Y. (2019). Molecular mimicry: Key contributors to the pathogenesis of autoimmune diseases. Frontiers in Immunology, 10, 2345. https://doi.org/10.3389/fimmu.2019.02345
[35] Malik, A., & Kanneganti, T. D. (2017). Inflammasome activation and assembly at a glance. Journal of Cell Science, 130(23), 3955-3963. https://doi.org/10.1242/jcs.207365
[36] Marson, A., Kohli, R. M., & Garcia, C. A. (2020). CRISPR-based therapies: Challenges and opportunities. Cell, 181(3), 514-520. https://doi.org/10.1016/j.cell.2020.03.023
[37] Mestas, J., & Hughes, C. C. (2004). Of mice and not men: Differences between mouse and human immunology. Journal of Immunology, 172(5), 2731-2738. https://doi.org/10.4049/jimmunol.172.5.2731
[38] Molina-Cerrillo, J., Alonso-Gordoa, T., Gajate, P., & Pandiella, A. (2019). Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treatment Reviews, 72, 73-88. https://doi.org/10.1016/j.ctrv.2018.11.006
[39] Mullin, E. (2020). The cost of chimeric antigen receptor T-cell immunotherapy: A primer for cancer patients. JAMA Oncology, 6(7), 1032-1036. https://doi.org/10.1001/jamaoncol.2020.0805
[40] Muramatsu, M., Kinoshita, K., & Nagaoka, H. (2020). Mechanisms of somatic hypermutation and class switch recombination in B cells. Nature Reviews Immunology, 20(1), 5-19. https://doi.org/10.1038/s41577-019-0219-3
[41] Murphy, K., & Weaver, C. (2016). Janeway's immunobiology (9th ed.). Garland Science.
[42] O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015). The JAK-STAT pathway: Implications for autoimmunity and therapy. Nature Reviews Drug Discovery, 14(6), 399-414. https://doi.org/10.1038/nrd4738
[43] Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., & Hymowitz, S. G. (2016). Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annual Review of Immunology, 34, 671-705. https://doi.org/10.1146/annurev-immunol-032315-021622
[44] Papalexi, E., & Satija, R. (2018). Single-cell RNA sequencing to explore immune cell heterogeneity. Nature Reviews Immunology, 18(1), 35-45. https://doi.org/10.1038/nri.2017.76
[45] Papayannopoulos, V. (2018). Neutrophil extracellular traps in immunity and disease. Nature Reviews Immunology, 18(2), 134-147. https://doi.org/10.1038/nri.2017.105
[46] Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi.org/10.1038/nrd.2017.243
[47] Park, C. O., & Kupper, T. S. (2015). The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nature Medicine, 21(7), 688-697. https://doi.org/10.1038/nm.3883
[48] Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., & Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine, 383(27), 2603-2615. https://doi.org/10.1056/NEJMoa2034577
[49] Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2020). Regulatory T cells and immune tolerance. Cell, 133(5), 775-787. https://doi.org/10.1016/j.cell.2020.10.003
[50] Schenkel, J. M., & Masopust, D. (2019). Tissue-resident memory T cells. Immunity, 41(6), 886-897. https://doi.org/10.1016/j.immuni.2019.12.002
[51] Schmidt, A., Oberle, N., & Krammer, P. H. (2018). Molecular mechanisms of Treg-mediated T cell suppression. Frontiers in Immunology, 3(51), 1-7. https://doi.org/10.3389/fimmu.2018.00051
[52] Shao, Y., & Qin, Z. (2019). The immunology of HIV/AIDS: Mechanism and application. Frontiers in Immunology, 10, 2945. https://doi.org/10.3389/fimmu.2019.02945
[53] Sharma, A., & Das, D. (2021). CRISPR-Cas9: A new era of genome editing in immunology. Journal of Immunology Research, 2021, 6646460. https://doi.org/10.1155/2021/6646460
[54] Sharpe, A. H., & Pauken, K. E. (2018). The diverse functions of the PD-1 inhibitory pathway. Nature Reviews Immunology, 18(3), 153-167. https://doi.org/10.1038/nri.2018.1
[55] Shrestha, S., Irvin, M. R., & Taylor, K. D. (2018). Pharmacogenomics in the treatment of HIV: An update on its applications. Pharmacogenomics Journal, 18(5), 767-776. https://doi.org/10.1038/s41397-018-0022-9
[56] Skyler, J. S., Krischer, J. P., Wolfsdorf, J., Cowie, C., Palmer, J. P., Greenbaum, C., & Mahon, J. (2017). Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial–Type 1. Diabetes Care, 38(7), 1222-1228. https://doi.org/10.2337/dc14-0788
[57] Smolen, J. S., Aletaha, D., & McInnes, I. B. (2019). Rheumatoid arthritis. The Lancet, 388(10055), 2023-2038. https://doi.org/10.1016/S0140-6736(16)30173-8
[58] Takeuchi, O., & Akira, S. (2018). Pattern recognition receptors and inflammation. Cell, 140(6), 805-820. https://doi.org/10.1016/j.cell.2010.01.022
[59] Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. (2020). The trinity of COVID-19: Immunity, inflammation, and intervention. Nature Reviews Immunology, 20(6), 363-374. https://doi.org/10.1038/s41577-020-0311-8
[60] Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., Del Carmen Morales, L., Gonzaga, J. R., & Combe, B. (2017). Baricitinib versus placebo or adalimumab in rheumatoid arthritis. The New England Journal of Medicine, 376(7), 652-662. https://doi.org/10.1056/NEJMoa1608345
[61] Tsou, P. S., Sawalha, A. H., & Coit, P. (2020). Epigenetics in the pathogenesis of systemic lupus erythematosus and rheumatoid arthritis. Cellular and Molecular Immunology, 17(6), 611-618. https://doi.org/10.1038/s41423-020-0451-6
[62] Venables, P. J., & Maini, R. N. (2014). Clinical significance of autoantibodies in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 43(3), 255-258. https://doi.org/10.3109/03009742.2014.882328
[63] Villadangos, J. A., & Young, L. (2020). Antigen-presentation properties of dendritic cells. Annual Review of Immunology, 38, 723-748. https://doi.org/10.1146/annurev-immunol-071319-102436
[64] Wang, X., He, Z., Zhang, C., & Liu, C. (2022). Bystander activation of T cells and its role in autoimmune diseases. Journal of Translational Autoimmunity, 5, 100146. https://doi.org/10.1016/j.jtauto.2022.100146
[65] Wei, S. C., Duffy, C. R., & Allison, J. P. (2018). Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery, 8(9), 1069-1086. https://doi.org/10.1158/2159-8290.CD-18-0367
[66] Wheeler, R. T., Kombe, D., Agarwala, S. D., & Fink, G. R. (2016). Dynamic, morphotype-specific Candida albicans β-glucan exposure during infection and drug treatment. PLoS Pathogens, 12(12), e1005960. https://doi.org/10.1371/journal.ppat.1005960
[67] Wu, H., Zeng, J., Yin, P., & Liu, L. (2020). Environmental risk factors for rheumatoid arthritis: A review of the evidence. Autoimmunity Reviews, 19(12), 102646. https://doi.org/10.1016/j.autrev.2020.102646
[68] Zheng, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J. M., Chu, T. T., & Rudensky, A. Y. (2020). Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T H 2 responses. Nature, 458(7236), 351-356. https://doi.org/10.1038/nature07774
[69] Zhu, J., & Paul, W. E. (2018). CD4 T cells: Fates, functions, and faults. Immunity, 41(6), 1-16. https://doi.org/10.1016/j.immuni.2018.12.006
[70] Zhu, W., & Ware, J. H. (2018). Host-pathogen interactions in intracellular bacterial infections. Cell, 173(6), 1370-1382. https://doi.org/10.1016/j.cell.2018.05.022